In continuation of our earlier intimation dated December 16, 2025, and subsequent deferment notice dated December 22, 2025, we wish to inform you that the meeting of the Board of Directors ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dr Lalchandani Labs Ltd has approved the terms of a proposed Rights Issue of equity shares at a Board meeting held on January 20, 2026. The company will issue 43,32,000 fully paid-up equity shares of face value ₹10 each, aggregating to about ₹4.33 crore, at a price of ₹10 per share (i.e., at par). Eligible shareholders will get 1 rights share for every 1 share held (1:1 ratio), taking total outstanding shares from about 43.33 lakh to 86.65 lakh on full subscription. The record date has been fixed as January 27, 2026, with the issue opening on February 4, 2026 and closing on February 20, 2026.
For existing shareholders, this is a dilutive fund raise at face value; they will need to invest additional capital to maintain their stake. The 1:1 entitlement at par price is significant for a small-cap and may pressure the stock in the short term, though it also strengthens the company's equity base if fully subscribed.